Myriad Genetics (MYGN) Long-Term Investments (2010 - 2023)

Myriad Genetics (MYGN) has 14 years of Long-Term Investments data on file, last reported at $6.2 million in Q2 2023.

• Long-Term Investments for Q2 2023 came in at $6.2 million, down 92.1% year-over-year; the trailing twelve-month figure through Jun 2023 was $6.2 million (down 92.1% YoY), and the FY2022 annual result was $54.8 million, down 7.12% from the prior year.
• Long-Term Investments fell to $6.2 million in Q2 2023 per MYGN's latest filing, from $30.4 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $78.5 million in Q2 2022 and troughed at $6.2 million in Q2 2023.
• A 5-year average of $42.8 million and a median of $45.2 million in 2020 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments soared 494.96% in 2022, then sank 92.1% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $47.6 million in 2019, then slumped by 55.88% to $21.0 million in 2020, then jumped by 180.95% to $59.0 million in 2021, then retreated by 7.12% to $54.8 million in 2022, then sank by 88.69% to $6.2 million in 2023.
• Business Quant data shows MYGN's Long-Term Investments at $6.2 million in Q2 2023, $30.4 million in Q1 2023, and $54.8 million in Q4 2022.